Hematology Oncology Edition: Top Headlines for Week of November 21, 2022

In this edition, lung cancer screening critically low across the U.S, first in-human CRISPR test with gene replacement, racial and economic segregation linked to higher cancer mortality rates, and more.

Read the full coverage here:

Lung cancer screening rates in US ‘simply unacceptable’

First CRISPR-based cell therapy to use gene replacement feasible, safe for solid tumors

Racial, economic segregation linked to cancer mortality

Onivyde regimen extends OS in metastatic pancreatic ductal adenocarcinoma

Immunotherapy a ‘significant improvement’ for treatment of multiple myeloma

References:

Davies FE, et al. New therapeutic agents for relapsed/refractory multiple myeloma: CAR T and bispecific antibodies. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.

Foy SP, et al. Abstract 1478. Presented at: Society for Immunotherapy of Cancer Annual Meeting; Nov. 8-12, 2022; Boston.

Press Release

Press Release

Zhang L, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5382.